Larvin

Clopidogrel, the active ingredient in Larvin, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It helps prevent thrombotic events in patients with atherosclerotic disease, acute coronary syndrome, and after percutaneous coronary intervention.

GNH USA supplies Larvin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network spans multiple continents, ensuring timely delivery and compliance with local regulatory requirements.

Clopidogrel is indicated for reducing platelet aggregation in cardiovascular disease states.

- Atherosclerotic disease: lowers risk of myocardial infarction, stroke and cardiovascular death. - Acute coronary syndrome: prevents recurrent ischemic events such as heart attack. - Post‑percutaneous coronary intervention (PCI): reduces incidence of stent thrombosis and related complications.

Clopidogrel may cause a variety of adverse reactions, ranging from common, mild events to rare but serious conditions.

Common Side Effects: - Bleeding gums: mild oral bleeding. - Bruising: easy bruising of skin. - Diarrhea: loose stools. - Nausea: occasional nausea. - Rash